Fulcrum Therapeutics, Inc.
FULC
$3.74
$0.030.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | 10.39% | -22.21% | -31.10% | -43.45% | -45.72% |
| Gross Profit | -10.39% | -292.97% | -362.86% | -491.88% | -647.78% |
| SG&A Expenses | 1.45% | -10.83% | -21.35% | -24.59% | -25.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.76% | -4.26% | -15.09% | -25.41% | -27.70% |
| Operating Income | -4.76% | -731.99% | -327.39% | -187.02% | -152.36% |
| Income Before Tax | -16.10% | -14,824.71% | -669.97% | -297.00% | -261.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.10% | -14,824.71% | -669.97% | -297.00% | -261.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.10% | -14,824.71% | -669.97% | -297.00% | -261.84% |
| EBIT | -4.76% | -731.99% | -327.39% | -187.02% | -152.36% |
| EBITDA | -5.07% | -853.19% | -357.10% | -200.37% | -163.20% |
| EPS Basic | 0.04% | -2,360.30% | -498.08% | -305.92% | -266.26% |
| Normalized Basic EPS | 7.68% | -8,429.76% | -618.79% | -357.99% | -256.30% |
| EPS Diluted | 0.31% | -1,479.92% | -429.20% | -276.98% | -244.80% |
| Normalized Diluted EPS | 7.68% | -3,395.12% | -543.03% | -325.95% | -236.63% |
| Average Basic Shares Outstanding | 16.35% | 10.82% | 5.34% | -2.77% | -2.62% |
| Average Diluted Shares Outstanding | 16.35% | 10.19% | 4.74% | -3.31% | -3.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |